Chipmaker Nvidia is pushing further into the business of finding new medicines with artificial intelligence.
According to Reuters, Nvidia is deepening its bets on AI in drug discovery through an investment in Recursion, a company that uses AI to help identify potential new drugs. The headline frames it as part of a broader, ongoing push rather than a one-off move.
That reading is reinforced by a separate report from Crypto Briefing, which says Nvidia is also investing in Generate Biomedicines, another AI-driven drug discovery firm. Crypto Briefing describes the effort as targeting a $1.8 trillion market.
Taken together, the two reports point to the same pattern: Nvidia, best known for the chips that power AI systems, is putting money directly into companies that apply that AI to the slow, expensive work of discovering new treatments.
The sources here are brief, and they do not spell out the size of either investment or the specific terms. What they establish is the direction of travel — Nvidia backing more than one AI biotech, and doing so in a market that Crypto Briefing pegs in the trillions of dollars.
Why it matters: when the company supplying the computing engine for the AI boom starts investing in the drug-discovery firms that run on that hardware, it signals that AI's push into pharmaceuticals is moving from promise toward real commercial bets.